Granted Patent
B2
US 12,360,118 · App. 15/776,161 · Granted Jul 15, 2025
Method for protein kinase activity ranking
Inventors:
Pedro Rodriguez Cutillas (London, GB); Edmund Wilkes (London, GB); Pedro Casado-Izquierdo (London, GB)
Assignee:
KINOMICA LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides a method of quantifying the activity of a protein modifying enzyme in a sample, comprising calculating the value K for said protein-modifying enzyme on the basis of the number of modified peptides in a sample that are substrates of said protein modifying enzyme, the intensity of the modified peptides, each modified peptide in the sample that is a substrate of said protein modifying enzyme, the total number of modified peptides in the sample, the intensity of the modified peptides and all of the modified peptides in the sample. A method of quantifying the activity of a protein modifying enzyme in a sample, comprising calculating the value SC for said protein-modifying enzyme on the basis of a reduction in proliferation using an inhibitor at an inhibitor concentration at which proliferation is measured and the “in vitro” IC50i of the inhibitor against a primary target is also provided. The invention further provides methods of identifying inhibitors with which to treat a patient, methods of treatment, a computer readable medium, a computer program product and devices for carrying out the methods.
Claims (83)
1. A method of treating a patient in need thereof with an inhibitor of a protein-modifying enzyme, comprising:
(i) identifying and/or quantifying modified peptides in a sample from the patient using mass spectrometry (MS) comprising:
(a) adding reference modified peptides to peptides obtained from the sample to produce a mixture of peptides and reference modified peptides;
(b) carrying out mass spectrometry on the mixture to obtain data relating to the peptides from the sample; and
(c) comparing the data relating to the peptides from the sample with data in a database of modified peptides to identify modified peptides in the sample;
(ii) calculating a value K for each protein-modifying enzyme in the sample taken from said patient according to
K
=
∑
i
=
1
m
α
i
∑
j
=
1
l
β
j
,
wherein:
m=the number of modified peptides in the sample that are substrates of the protein-modifying enzyme;
α=the intensity of the modified peptides i;
i=each modified peptide in the sample that is a substrate of the protein-modifying enzyme;
l=the total number of modified peptides in the sample;
β=the intensity of the modified peptides j; and
j=all of the modified peptides in the sample;
(iii) identifying the protein-modifying enzyme with the highest value K, wherein the protein-modifying enzyme is selected from: protein kinase A, protein kinase B, protein kinase C, protein kinase G, tyrosine kinase, tyrosine kinase-like kinase, calcium-dependent protein kinase, calmodulin-dependent protein kinase, the casein kinase 1 group; CMGC group, the homologues of yeast Sterile 7, Sterile 11, and Sterile 20 kinases;
(iv) selecting an inhibitor that targets the protein-modifying enzyme with the highest value K; and
(v) administering said inhibitor to said patient at a therapeutically effective amount, so as to treat the patient in a personalized manner.
2. The method according to claim 1 , wherein the value K is modified by a correction factor and is calculated for said protein-modifying enzyme as follows:
K
=
∑
i
=
1
m
α
i
∑
j
=
1
l
β
j
*
(
m
t
)
1
/
2
wherein t=the total number of known target modified peptides for said protein-modifying enzyme.
3. The method according to claim 1 , wherein the inhibitor is AZD-5438, GF-109203X, PF-3758309, GSK1120212, MK-2206, KU-0063794, TAK 715, PKC-412, TBB, or C4945.
4. The method according to claim 1 , wherein the database of modified peptides is compiled by a method comprising:
i) obtaining peptides from a sample;
ii) enriching modified peptides from the peptides obtained in step i);
iii) carrying out liquid chromatography-tandem mass spectrometry (LC-MS/MS) on the enriched modified peptides obtained in step ii);
iv) comparing the modified peptides detected in step iii) to a known reference database in order to identify the modified peptides; and
v) compiling data relating to the modified peptides identified in step iv into a database.
5. The method according to claim 4 , wherein the data relating to the peptides in the sample comprises the mass to charge (m/z) ratio, charge (z), and relative retention time of the peptides.
6. The method according to claim 4 , wherein step ii) is carried out using multidimensional chromatography.
7. The method according to claim 6 , wherein the multidimensional chromatography is carried out using strong cation exchange high performance liquid chromatography (SCX-HPLC), immobilized metal ion affinity chromatography (IMAC), and titanium dioxide (TiO2) chromatography.
8. The method according to claim 6 , wherein the multidimensional chromatography is carried out using anion exchange high performance liquid chromatography (SAX-HPLC), immobilized metal ion affinity chromatography (IMAC), and titanium dioxide (TiO2) chromatography.
9. The method according to claim 4 , wherein step ii) is carried out using antibody-based methods.
10. The method according to claim 4 , wherein step iv) is carried out using a search engine that uses mass spectrometry data to identify proteins in one or more primary sequence databases, including the known reference database.
11. The method according to claim 4 , wherein the data relating to the modified peptides identified in step iv) is selected from the group consisting of identity of the modified peptide, mass to charge (m/z) ratio, charge (z), and relative retention time of the modified peptide.
12. The method according to claim 1 , wherein step b) further comprises enriching modified peptides from said mixture of peptides and reference modified peptides to produce a mixture of enriched modified peptides, and step c) comprises carrying out mass spectrometry (MS) on said mixture of enriched modified peptides to obtain data relating to the modified peptides in the sample.
13. The method according to claim 12 , wherein the step of enriching modified peptides is carried out using chromatography.
14. The method according to claim 13 , wherein the chromatography is selected from the group consisting of immobilized metal ion affinity chromatography (IMAC), titanium dioxide (TiO 2 ) chromatography, and zirconium dioxide (ZrO 2 ) chromatography.
15. The method according to claim 12 , wherein the step of enriching modified peptides is carried out using antibody-based methods.
16. The method according to claim 12 , wherein said mass spectrometry (MS) in step c) is liquid chromatography-mass spectrometry (LC-MS).
17. The method according to claim 1 , wherein the MS technique uses isotope labels for quantification.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 13, 2021
From: QUEEN MARY UNIVERSITY OF LONDON
To: KINOMICA LIMITED
Reel/Frame 056229/0166 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 25, 2018
From: CUTILLAS, PEDRO RODRIGUEZ; WILKES, EDMUND; CASADO-IZQUIERDO, PEDRO
To: QUEEN MARY UNIVERSITY OF LONDON
Reel/Frame 046456/0347 →
Priority Claims (1)
GB 1520178
· Nov 16, 2015
· national
Continuity (2)
Related Publication
20210223258A9
· Jul 22, 2021
References Cited (182)
US 6818484B2
· Voutsas
· 2004
[cited by applicant]
US 20030153007A1
· Chen et al.
· 2003
[cited by applicant]
US 20050164324A1
· Gygi
· 2005
[cited by applicant]
US 20060148093A1
· Gygi et al.
· 2006
[cited by applicant]
US 20080221802A1
· Oda et al.
· 2008
[cited by applicant]
US 20120070844A1
· Rodriguez Cutillas
· 2012
[cited by examiner]
EP 2124051
· 2009
[cited by applicant]
EP 2013054764
· 2013
[cited by applicant]
WO 2003097867
· 2003
[cited by applicant]
WO 2003102220
· 2003
[cited by applicant]
WO 2005106923
· 2005
[cited by applicant]
WO 2007127767
· 2007
[cited by applicant]
WO 2007144606
· 2007
[cited by applicant]
WO 2009054939
· 2009
[cited by applicant]
WO 2010006333
· 2010
[cited by applicant]
WO 2010040024
· 2010
[cited by applicant]
WO 2010119261
· 2010
[cited by applicant]
WO 2011109440
· 2011
[cited by applicant]
WO 2013132075
· 2013
[cited by applicant]
H Patterson, R Nibbs, I McInnes, S Siebert, Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases, Clinical and Experimental Immunology, vol. 176, Issue 1, Apr. 2014, pp. 1-10 (Year: 2014).
[cited by examiner]
Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochemistry. Jun. 4, 2013;52(22):3797-806. (Year: 2013).
[cited by examiner]
McLachlin DT, Chait BT. Analysis of phosphorylated proteins and peptides by mass spectrometry. Curr Opin Chem Biol. Oct. 2001;5(5):591-602. (Year: 2001).
[cited by examiner]
Wu HY, Tseng VS, Liao PC. Mining phosphopeptide signals in liquid chromatography-mass spectrometry data for protein phosphorylation analysis. J Proteome Res. May 2007;6(5):1812-21. (Year: 2007).
[cited by examiner]
Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS. Evaluation of enrichment techniques for mass spectrometry: identification of tyrosine phosphoproteins in cancer cells. J Mol Diagn. Apr. 2007;9(2):169-77. (Year:…
[cited by examiner]
Di Palma S, Hennrich ML, Heck AJ, Mohammed S. Recent advances in peptide separation by multidimensional liquid chromatography for proteome analysis. J Proteomics. Jul. 16, 2012;75(13):3791-813. (Year: 2012).
[cited by examiner]
Worthington, J., Cutillas, P.R. and Timms, J.F. (2011), IMAC/TiO2 enrich for peptide modifications other than phosphorylation: Implications for chromatographic choice and database searching in phosphoproteomics. Proteom…
[cited by examiner]
Alcolea MP, Cutillas PR. In-depth analysis of protein phosphorylation by multidimensional ion exchange chromatography and mass spectrometry. Methods Mol Biol. 2010;658:111-26. (Year: 2010).
[cited by examiner]
Salovska, Barbora, Tichy, Ales, Rezacova, Martina, Vavrova, Jirina and Novotna, Eva. “Enrichment strategies for phosphoproteomics: state-of-the-art” Reviews in Analytical Chemistry, vol. 31, No. 1, 2012, pp. 29-41. (Yea…
[cited by examiner]
Engholm-Keller K, Birck P, Størling J, Pociot F, Mandrup-Poulsen T, Larsen MR. TiSH—a robust and sensitive global phosphoproteomics strategy employing a combination of TiO2, SIMAC, and HILIC. J Proteomics. Oct. 22, 2012…
[cited by examiner]
Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. Oct. 2015;100:1-23. (Year: 2015).
[cited by examiner]
Wilkes “Phosphoproteomic investigation of kinase signalling network plasticity in response to chronic PI3K and mTORC1/2 inhibition” Thesis submitted on Feb. 5, 2015 and made available Sep. 30, 2015.
[cited by applicant]
Vojvodic et al., “A Phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines”, Current Drug Discovery Technologies, 2013, 10, pp. 283-304.
[cited by applicant]
Rix et al., “Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and nonkinase targets”, Blood, 2007, 110(12), pp. 4055-4063.
[cited by applicant]
Pan et al., “Global Effects of kinase inhibitors on signalling networks revealed by quantitative phosphoproteomics”, Molecular and Cellular Proteomics, 2009, 8.12, pp. 2796-2808.
[cited by applicant]
Wilkes et al., “Deep analysis of signaling plasticity in a breast cancer kinase network during acquisition of resistance to PI3K and mTORC1/2 inhibitors”, NCRI Cancer Conference abstract, 2013.
[cited by applicant]
Wilkes et al., “Empirical inference of circuitry and plasticity in a kinase signalling network” PNAS, 2015, 112(25), pp. 7719-7724.
[cited by applicant]
Kholodenko et al., “Untangling the wires: A strategy to trace functional interactions in signaling and gene networks”, PNAS, 2002, 99(20), pp. 12841-12846.
[cited by applicant]
Mukherjee et al., “Network inference using informative priors”, PNAS, 2008, 105(38), pp. 14313-14318.
[cited by applicant]
Prill et al., “Crowdsourcing Network Inference: The DREAM Predictive Signaling Network Challenge”, Sci Signal, 2012, 4(189), mr7.
[cited by applicant]
Linding et al., “Systematic Discovery of In Vivo Phosphorylation Networks”, Cell, 2007, 129(7), pp. 1415-1426.
[cited by applicant]
Carlson et al., “Large-scale Discovery of ERK2 Substrates Identifies ERK-Mediated Transcriptional Regulation by ETV3”, Sci Signal. 2013, 4(196): rs11.
[cited by applicant]
Bensimon et al., “Mass Spectrometry-Based Proteomics and Network Biology”, Annu Rev Biochem, 2012, 81, pp. 379-405.
[cited by applicant]
Casado et al., “Kinase-substrate enrichment analysis provides insights into the heterogeneity of signalling pathway activation in leukaemia cells”, Science Signalling, 2013, 6(268):rs6.
[cited by applicant]
Casado et al., “Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors”, Genome Biology, 2013, 14:R37.
[cited by applicant]
Bolstad et al., “A Comparison of Normalization Methods for High Density Oligonucleotide Array Data Based on Variance and Bias”, Bioinformatics, 2003, 19(2), pp. 185-193.
[cited by applicant]
Smyth, “Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments”, Stat Appl Genet Molec Biol, 2004, 3(1), Article 3.
[cited by applicant]
R Core Team (2013), http://www.R-project.org, 2013.
[cited by applicant]
Alcolea et al., “Phosphoproteomic Analysis of Leukemia Cells under Basal and Drug-treated Conditions Identifies Markers of Kinase Pathway Activation and Mechanisms of Resistance”, Mol Cell Proteomics, 2012, 11.8, pp. 45…
[cited by applicant]
Tsou et al.,“IDEAL-Q, an automated tool for label-free quantitation analysis using an efficient peptide alignment approach and spectral data validation”, Mol Cell Proteomics, 2009, 9.1, pp. 131-144.
[cited by applicant]
Mann et al., “ProteinQuant Suite: a bundle of automated software tools for label-free quantitative proteomics”, Rapid Commun Mass Spectrom, 2008, 22, pp. 3823-3834.
[cited by applicant]
Escher et al., “Using iRT, a normalized retention time for more targeted measurement of peptides”, Proteomics, 2012, 12, pp. 1111-1121.
[cited by applicant]
Wickham, “Elegant Graphics for Data Analysis”, Journal of Statistical Software, 2010, 35(1), pp. 1-3.
[cited by applicant]
Warnes et al., “Various R programming tools for plotting data”, Package ‘gplots’, 2016, 3.0.1, pp. 1-68.
[cited by applicant]
Wickham, “Reshaping data with the reshape package”, http://had.co.nz/reshape, 2006, pp. 1-25.
[cited by applicant]
Csardi et al., “The igraph software package for complex network research”, InterJournal Complex Systems:1695, 2005, pp. 1-9.
[cited by applicant]
Shannon et al., “RCytoscape: tools for exploratory network analysis”, BMC Bioinformatics, 2013, 14(217), pp. 1-9.
[cited by applicant]
Shannon et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks”, Genome Res, 2003, 13(11), pp. 2498-2504.
[cited by applicant]
Gobbi et al., “Fast randomization of large genomic datasets while preserving alteration counts”, Bioinformatics, 2014, 30, pp. i617-i623.
[cited by applicant]
Kim et al., “PAGE: parametric analysis of gene set enrichment”, BMC Bioinformatics, 2005, 6(144), pp. 1-12.
[cited by applicant]
Lindsley et al., “Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors”, Bioorg Med Chem Lett, 2005, 15, pp. 761-764.
[cited by applicant]
Rehan et al., “Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206”, PLoS One, 2014, 9(10):e109705.
[cited by applicant]
Hirai et al., “MK-2206, an allosteric Akt inhibitor, enhances the antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo”, Mol Cancer Ther, 2010, 9(7), pp. 1956-1967.
[cited by applicant]
Sumi et al., “The newly synthesized selective Ca2+/calmodulin dependent protein kinase-II inhibitor KN-93 reduces dopamine contents in PC12H cells”, Biochem Biophys Res Commun, 1991, 181(3), pp. 968-975.
[cited by applicant]
Tokumitsu et al., “KN-62, 1-N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl 4-phenylpiperazin E, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase-II”, J Biol Chem, 1990, 265(8), pp. 4315-4320.
[cited by applicant]
Fry et al., “Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor”, PNAS, 1998, 95, pp. 12022-12027.
[cited by applicant]
Bos et al., “PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner”, Clin Cancer Res, 1997, 3, pp. 2099-210…
[cited by applicant]
Hancock et al., “Identification of novel extracellular signal-regulated kinase docking domain inhibitors”, J Med Chem, 2005, 48, pp. 4586-4595.
[cited by applicant]
Ohori et al., “Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex”, Biochem Biophys Res Commun, 2005, 336, pp. 357-363.
[cited by applicant]
Gilmartin et al., “GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition”, Clin Cancer Res, 2011, 17(5), pp. 989-1000.
[cited by applicant]
Roberts et al., “Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer”, Oncogene, 2007, 26, pp. 3291-3310.
[cited by applicant]
Favata et al., “Identification of a novel inhibitor of mitogen-activated protein kinase kinase”, J Biol Chem, 1998, 273(29), pp. 18623-18632.
[cited by applicant]
Garcia-Martinez et al., “Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)”, Biochem J, 2009, 421, pp. 29-42.
[cited by applicant]
Liu et al., “Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin- 3-yl)benzo h 1,6 naphthyridin-2(1H) one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for…
[cited by applicant]
Pearce et al., “Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)”, Biochem J, 2010, 431, pp. 245-255.
[cited by applicant]
Okuzumi et al., “Inhibitor hijacking of Akt activation”, Nat Chem Biol, 2009, 5(7), pp. 484-493.
[cited by applicant]
Raynaud et al., “Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941”, Mol Cancer Ther, 2010, 8(7), pp. 1725-1738.
[cited by applicant]
Martiny-Baron et al., “Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976”, J Biol Chem, 1993, 268(13), pp. 9194-9197.
[cited by applicant]
Toullec et al., “The bisindolylmaleimide GF-109203X is a potent and selective inhibitor of protein kinase C”, J Biol Chem, 1991, 266(24), pp. 15771-15781.
[cited by applicant]
McCluskey et al., “Serine-threonine protein phosphatase inhibitors: Development of potential therapeutic strategies”, J Med Chem, 2002, 45(6), pp. 1151-1175.
[cited by applicant]
Li et al., “Cantharidin-binding protein—identification as protein phosphatase-2A”, PNAS, 1992, 89, pp. 11867-11870.
[cited by applicant]
Tamura et al., “Development of specific Rho-kinase inhibitors and their clinical application”, Biochim Biophys Acta, 2005, 1754, pp. 245-252.
[cited by applicant]
Shizaki et al., “Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases”, Mol Pharmacol, 2000, 57, pp. 976-983.
[cited by applicant]
Du et al., “Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies”, Oncogene, 2015, 34, pp. 3215-3225.
[cited by applicant]
Papin et al., “Reconstruction of cellular signaling networks and analysis of their properties”, Nat Rev Mol Cell Biol, 2005, 6, pp. 99-111.
[cited by applicant]
Jorgensen et al., “Simplistic pathways or complex networks?”, Curr Opin Genet Dev, 2010, 20, pp. 15-22.
[cited by applicant]
Hsu et al., “The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling”, Science, 2011, 332(6035), pp. 1317-1322.
[cited by applicant]
Goltsov et al., “Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signaling network after HER2 inhibition”, Cell Signal, 2012, 24, pp. 493-504.
[cited by applicant]
Goltsov et al., “Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition”, Cell Signal, 2011, 23, pp. 407-416.
[cited by applicant]
Posch et al., “Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo”, PNAS, 2013, 110(10), pp. 4015-4020.
[cited by applicant]
Renshaw et al., “Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo”, Clin Cancer Res, 2013, 19(21), pp. 5940-5951.
[cited by applicant]
Roberts et al., “Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancel models”, Clin Cancer Res, 2012, 18(19), pp. 5290-5303.
[cited by applicant]
Sarbassov et al., “Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton”, Curr Biol, 2004, 14, pp. 1296-1302.
[cited by applicant]
Hay et al., “Upstream and downstream of mTOR”, Genes Dev, 2004, 18, pp. 1926-1945.
[cited by applicant]
Kumar et al., “Activation of a non-genomic Pim-1/Bad-Pser75 module is required for an efficient pro-survival effect of Bcl-xL induced by androgen in LNCaP cells”, Int J Biochem Cell Biol, 2011, 43, pp. 594-603.
[cited by applicant]
Vincent et al., “Control of cell survival by IGF signaling pathways”, Growth Horm IGF Res, 2002, 12, pp. 193-197.
[cited by applicant]
Ciaccio et al., “Systems analysis of EGF receptor signaling dynamics with microwestern arrays”, Nat Methods, 2010, 7(2), pp. 148-155.
[cited by applicant]
Munugalavadla et al., “The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma”, Oncogene, 2014, 33, pp. 316-325.
[cited by applicant]
Oda et al., “A comprehensive pathway map of epidermal growth factor receptor signaling”, Mol Sys Biol, 2005, 2005.0010.
[cited by applicant]
Kanehisa et al., “KEGG for integration and interpretation of large-scale molecular data sets”, Nucleic Acids Res, 2012, 40, Database issue:D109-114.
[cited by applicant]
Dutta et al., “A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes”, Br J Cancer, 2012, 106, pp. 1107-1116.
[cited by applicant]
Hughes et al., “Functional discovery via a compendium of expression profiles”, Cell, 2000, 102, pp. 109-126.
[cited by applicant]
Muranen et al., “Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells”, Cancer Cell, 2012, 21(2), pp. 227-239.
[cited by applicant]
Elkabets et al., “mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 alpha Inhibitors in PIK3CA-Mutant Breast Cancer”, Sci Transl Med, 2013, 5(196): 196ra99.
[cited by applicant]
Klempner et al., “What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway”, Cancer Discov, 2013, 3(12), pp. 1345-1354.
[cited by applicant]
Lito et al., “Tumor adaptation and resistance to RAF inhibitors”, Nat Med, 2013, 19(11), pp. 1401-1409.
[cited by applicant]
Gerlinger et al., “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing”, N Eng J Med, 2012, 366(10), pp. 883-892.
[cited by applicant]
Le Gac et al., “Ecological and evolutionary dynamics of coexisting lineages during a long-term experiment with
[cited by applicant]
Samovski et al., “Regulation of AMPK activation by CD36 links fatty acid uptake to beta-oxidation”, Diabetes, 2015, 64, pp. 353-359.
[cited by applicant]
Liu et al., “Activated STING in a vascular and pulmonary syndrome”, The New England journal of medicine, 2014, 371(6), pp. 507-518.
[cited by applicant]
Forlenza et al., “Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease”, Journal of psychiatric research, 2011, 45, pp. 220-224.
[cited by applicant]
Samuels et al., “Oncogenic mutations of PIK3CA in human cancers”, Cell cycle,2004, 3(10), pp. e17-e19.
[cited by applicant]
Manning, “Challenges and opportunities in defining the essential cancer kinome”, Sci Signal, 2009, 2(63), pe15.
[cited by applicant]
Schlabach et al., “Cancer proliferation gene discovery through functional genomics”, Science, 2008, 319(5863), pp. 620-624.
[cited by applicant]
Grueneberg et al., “Kinase requirements in human cells: I. Comparing kinase requirements across various cell types”, PNAS, 2008, 105(43), pp. 16472-16477.
[cited by applicant]
Grueneberg et al., “Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines”, PNAS, 2008, 105(43), pp. 16490-16495.
[cited by applicant]
Chapman et al., “Improved survival with vemurafenib in melanoma with BRAF V600E mutation”, The New England Journal of Medicine, 2011, 364(26), pp. 2507-2516.
[cited by applicant]
Janku et al., “PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations”, Journal of Clinical Oncology, 2012, 30(8), pp. 777-782.
[cited by applicant]
Casado et al., “Environmental stress affects the activity of metabolic and growth factor signaling networks and induces autophagy markers in MCF7 breast cancer cells”, Molecular & Cellular Proteomics, 2014, 13(3), pp. 8…
[cited by applicant]
Rajeeve et al., “Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth”, Biochem J, 2013, 450, pp. 619-628.
[cited by applicant]
Daub et al., “Kinase-Selective Enrichment Enables Quantitative Phosphoproteomics of the Kinome across the Cell Cycle”, Cell, 2008, 31, pp. 438-448.
[cited by applicant]
Miraki-Moud et al., “Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo”, Blood, 2015, 125(26), pp. 4060-4068.
[cited by applicant]
Cox et al., “MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification”, Nature Biotechnology, 2008, 26(12), pp. 1367-1372.
[cited by applicant]
Cascante et al., “Metabolic control analysis in drug discovery and disease”, Nature Biotechnology, 2002, 20, pp. 243-249.
[cited by applicant]
Smyth, “Limma: Linear Models for Microarray Data”, Springer, New York, 2005, pp. 397-420.
[cited by applicant]
Miller et al., “Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer”, Breast Cancer Research, 2011, 13(224), pp. 1-12.
[cited by applicant]
Raynaud et al., “Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases”, Cacner Res, 2007, 67(12), pp. 5840-5850.
[cited by applicant]
Rajeeve et al., “Cross-species Proteomics Reveals Specific Modulation of Signaling in Cancer and Stromal Cells by Phosphoinositide 3-kinase (PI3K) Inhibitors”, Molecular and Cellular Proteomics, 2014, 13.6, pp. 1457-147…
[cited by applicant]
Benjamini et al., “Controling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing”, Journal of the Royal Statistical Society B, 1995, 57(1), pp. 289-300.
[cited by applicant]
Huang et al., “Applcation of Pearson Correlation Coefficient (PCC) and Kolmogorov-Smirnov Distance (KSD) Metrics to Identify Disease Specific Biomarker Genes”, BMC Bioinformatics, 2010, 11(suppl 4), pp. 1-2.
[cited by applicant]
Alcolea et al., “In-Depth Analysis of Protein Phosphorylation by Multidimensionallon Exchange Chromatography and Mass Spectrometry”, Meth Mol Biol, 2010, 658, pp. 111-126.
[cited by applicant]
Alcolea et al., “Increased Confidence in Large-Scale Phosphoprotemics Data by Complementary Mass Spectrometric Techniques and Matching of Phosphopeptide Data Sets”, J Proteome Res, 2009, 8(8), pp. 3808-3815.
[cited by applicant]
Alessi et al., “Molecular Basis for the Substrate Specificity of Protein Kinase B; Comparison with MAPKAP Kinase-1 and p70 S6 Kinase”, FEBS Lett, 1996, 399, pp. 333-338.
[cited by applicant]
Bantscheff et al., “Quantitative Chemical Proteomics Reveals Mechanisms of Action of Clinical ABL Kinase Inhibitors”, Nat Biotechnol, 2007, 25(9), pp. 1035-1044.
[cited by applicant]
Barglow et al., “Activity-based protein profiling for the functional annotation of enzymes”, Nat Methods, 2007, 4(10), pp. 822-827.
[cited by applicant]
Blagoev et al., “Temporal Analysis of Phosphotyrosine-dependent Signaling Networks by Quantitative Proteomics” Nat Biotech, 2004, 22(9), pp. 1139-1145.
[cited by applicant]
Blethrow et al., “Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates”, PNAS, 2008, 105(5), pp. 1442-1447.
[cited by applicant]
Bodenmiller et al. “Phosphoproteomic Analysis Reveals Interconnected System-Wide Responses to Perturbations of Kinases and Phosphatases in Yeast” Sci Signal, 2010, 3(153):rs4.
[cited by applicant]
Cartlidge et al., “The IRNA Methylase METTL 1 is Phosphorylated and Inactivated by PKB and RSK in vitro and in Cells”, Embo J, 2005, 24(9), pp. 1696-1705.
[cited by applicant]
Casado et al., “A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments” Mol Cell Proteomics, 2011, 10(1):M110 003079.
[cited by applicant]
Cutillas et al., “Biological signalling activity measurements using mass spectrometry”, J Biochem, 2011, 434, pp. 189-199.
[cited by applicant]
Cutillas et al., “Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line” Molecular & cel…
[cited by applicant]
Cutillas et al., “Quantitative profile for five murine core proteomnes using label-free functional proteomics” Mol Cell Proteomics, 2007, 6(9), pp. 1560-1573.
[cited by applicant]
Cutillas et al., “Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry”, Proc Natl Acad Sci, 2006, 103(24), pp. 8959-8964.
[cited by applicant]
Dayon et al., “Realative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags” Anal Chem, 2008, 80(8), pp. 2921-2931.
[cited by applicant]
Dinkel et al., “Phospho.ELM: a database of phosphorylation sites-update 2011”, Nucleic Acids Res, 2011, 39, D261-D267.
[cited by applicant]
Ficarro et al., “Automated immobilized metal affinity chromatography/nano-liquid chromatography/electrospray ionization mass spectrometry platform for profiling protein phosphorylation sites”, Rapid Commun Mass Spcetom,…
[cited by applicant]
Frewen et al., “Analysis of peptide MS/MS spectra from large-scale proteomics experiments using spectrum libraries”, Anal Chem, 2006, 78, pp. 5678-5684.
[cited by applicant]
Gerber et al., “Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS”, PNAS, 2003, 100(12), pp. 6940-6945.
[cited by applicant]
Gygi et al., “Quantitative analysis of complex protein mixtures using isotope-coded affinity tags”, Nat Biotechnology, 1999, 17, pp. 994-999.
[cited by applicant]
Hornbeck et al., “PhosphoSite: a bioinformatics resource dedicated to physiological protein phosphorylation”, Proteomics, 2004, 4, pp. 1551-1561.
[cited by applicant]
Huang et al., “Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.”, Nucleic Acids Research, 2009, 37(1), pp. 1-13.
[cited by applicant]
Hummel et al., “ProMEX: a mass spectral reference database for proteins and protein phosphorylation sites”, BMC Bioinformatics, 2007, 8, pp. 216.
[cited by applicant]
Kirkpatrick et al., “The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications”, Methods, 2005, 35(3), pp. 265-273.
[cited by applicant]
Knebel et al., “A Novel Method to Identify Protein Kinase Substrates: eEF2 Kinase is Phosphorylated and Inhibited by SAPK4/p388”, Embo J, 2001, 20(16), pp. 4360-4369.
[cited by applicant]
Kubota et al., “Sensitive Multiplexed Analysis of Kinase Activities and Activity-based Kinase Identification”, Nature Biotechnology, 2009, 27(10), pp. 933-940.
[cited by applicant]
Luo et al., “Global Impact of Oncogenic Src on a Phosphotyrosine Proteome”, J Proteome Res, 2008, 7, pp. 3447-3460.
[cited by applicant]
Miller et al., “Linear Motif Atlas for Phosphorylation-Dependent Signaling”, Sci Signal, 2008, 1(35):ra2.
[cited by applicant]
Montoya et al., “Characterization of a TiO2 enrichment method for label-free quantitative phosphoproteomics”, Methods, 2011, 54(4), pp. 370-378.
[cited by applicant]
Nita-Lazar et al., “Quantitative phosphoproteomics by mass spectrometry: past, present, and future”, Proteomics, 2008, 8(21), pp. 4433-4443.
[cited by applicant]
Olsen et al., “Global, in vivo, and site-specific phosphorylation dynamics in signaling networks”, Cell, 2006, 127, pp. 635-648.
[cited by applicant]
Pasa-Tolic et al., “Proteomic analyses using an accurate mass and time tag strategy”, Biotechniques, 2004, 37(4), pp. 621-624.
[cited by applicant]
Perkins et al., “Probability-based protein identification by searching sequence databases using mass spectrometry data”, Electrophoresis, 1999, 20, pp. 3551-3567.
[cited by applicant]
Ross et al., “Multiplexed protein quantitation in
[cited by applicant]
Ruse et al., “Quantitative dynamics of site-specific protein phosphorylation determined using liquid chromatography electrospray ionization mass spectrometry”, Anal Chem, 2002, 74(7), pp. 1658-1664.
[cited by applicant]
Savitski et al., “Confident Phosphorylation Site Localization Using the Mascot Delta Score”, Technol In nov Resources, 2011, 10, pp. 1-12.
[cited by applicant]
Schwartz et al., “An interative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets”, Nature Biotechnology, 2005, 23(11), pp. 1391.
[cited by applicant]
Smith et al., “Recent developments in mass spectrometry-based quantitative phosphoproteomics”, Biochem Cell Biol, 2008, 86(2), pp. 137-148.
[cited by applicant]
Steen et al., “Stable isotope-free relative and absolute quantification of protein phosphorylation stoichiometry by MS”, PNAS, 2005, 102(11), pp. 3948-3953.
[cited by applicant]
Thingholm et al., “Analytical strategies for phosphoproteomics”, Proteomics, 2009, 9, pp. 1451-1468.
[cited by applicant]
Wang et al., “SEMI-quantitation Strategy for Label-free Quantitative Profiling of Phosphoproteome in Lung Cancer of Different Invasive Potential”, Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied …
[cited by applicant]
Yang et al., “Applying a targeted label-free approach using LC-MS AMT tags to evaluate changes in protein phosphorylation following phosphatase inhibition”, J Proteome Res, 2007, 6(11), pp. 4489-4497.
[cited by applicant]
Yi et al., “Quantification of phosphorylation of insulin receptor substrate-1 by HPLC-ESI-MS/MS”, J Am Soc Mass Spectrom, 2006, 17(4), pp. 562-567.
[cited by applicant]
Yu et al., “A site-specific, multiplexed kinase activity assay using stable-isotope dilution and high-resolution mass spectometry”, PNAS, 2009, 106(28), pp. 11606-11611.
[cited by applicant]
Zhang et al., “Targeting cancer with small molecule kinase inhibitors” Nat Rev Cancer, 2009, 9(1), pp. 28-39.
[cited by applicant]
Zhou et al., “A systematic approach to the analysis of protein phosphorylation”, Nat Biotech, 2001, 19(4), pp. 375-378.
[cited by applicant]
Glinski et al., “Stable isotope labeling of phosphopeptides for multiparallel kinase target analysis and identification of phosphorylation sites” Rapid Communications in Mass Spectrometry, 2003, 17, pp. 1579-1584.
[cited by applicant]
Kirkpatrick et al., “Phosphoproteomic characterisation of DNA damage response in melanoma cells following MEK/PI3K dual inhibition”, PNAS, 2013, 110(48), pp. 19426-19431.
[cited by applicant]
Cutillas, “Deep analysis of signalling plasticity in a breast cancer kinase network during acquisition of resistance to PI3K and mTORC1/2 inhibitors”, NCI Cancer Conference, Nov. 4, 2013, Liverpool.
[cited by applicant]
Non-Final Office Action dated Jan. 22, 2021 in related U.S. Appl. No. 15/579,363.
[cited by applicant]
Final Office Action dated May 26, 2021 in related U.S. Appl. No. 15/579,363.
[cited by applicant]
U.S. Appl. No. 14/384,151, filed Sep. 9, 2014 which is the National Stage Entry of PCT Application No. PCT/EP2013/054764, filed Mar. 8, 2013.
[cited by applicant]
U.S. Appl. No. 15/579,363, filed Dec. 4, 2017 which is the National Stage Entry of PCT Application No. PCT/GB16/51639, filed Jun. 3, 2016.
[cited by applicant]